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Abstract
Background: Many people with multiple sclerosis experience problems with walking, which can make daily activities
difficult and often leads to falls. Foot sensation plays an important role in keeping the body balanced whilst walking;
however, people with multiple sclerosis often have poor sensation on the soles of their feet. Wearing a specially
designed shoe insole, which enhances plantar sensory information, could help people with multiple sclerosis to
walk better. This study will explore whether long-term wear of a textured insole can improve walking in people
with multiple sclerosis.
Methods: A prospective randomised controlled trial with two parallel groups will be conducted aiming to recruit
176 people with multiple sclerosis living in the community (Brisbane, Australia). Adults with a clinical diagnosis of
multiple sclerosis, Disease Steps score 1–4, who are ambulant over 100 m and who meet specific inclusion criteria will
be recruited. Participants will be randomised to a smooth control insole (n = 88) or textured insole (n = 88) group. The
allocated insole will be worn for 12-weeks within participants’ own footwear, with self-report wear diaries and
falls calendars being completed over this period. Blinded assessors will conduct two baseline assessments and
one post-intervention assessment. Gait tasks will be completed barefoot, wearing standardised footwear only, and
wearing standardised footwear with smooth and textured insoles. The primary outcome measure will be mediolateral
base of support when walking over even and uneven surfaces. Secondary measures include spatiotemporal gait
parameters (stride length, stride time variability, double-limb support time, velocity), gait kinematics (hip, knee,
and ankle joint angles, toe clearance, trunk inclination, arm swing, mediolateral pelvis/head displacement), foot
sensation (light touch-pressure, vibration, two-point discrimination) and proprioception (ankle joint position sense).
Group allocation will be concealed and all analyses will be based on an intention-to-treat principle.
Discussion: This study will explore the effects of wearing textured insoles over 12-weeks on gait, foot sensation
and proprioception in people with multiple sclerosis. The study has the potential to identify a new, evidence-based
footwear intervention which has the capacity to enhance mobility and independent living in people with multiple
sclerosis.
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Background
Falls are a major threat to the health and well-being of
people with multiple sclerosis (pwMS) [1, 2]. Up to 50 %
of pwMS report falling within the past 6 months, and
50 % of these falls result in injuries [3]. Impaired mobil-
ity and balance are two major risk factors for falls in
pwMS [2]. In one study, 85 % of pwMS reported gait
disturbances as their main complaint [4] and continued
loss of mobility amongst their greatest concerns for the
future [5]. Impaired walking in pwMS is typically charac-
terised by an increased mediolateral (ML) base of sup-
port, reduced stride length, step length and velocity, and
prolonged double-limb support time during level ground
walking, relative to healthy individuals [6–8]. Incipient
signs of deteriorating walking ability can even be ob-
served in the early stages of the disease [6–8]. Therefore,
interventions that effectively preserve or enhance walk-
ing capacity are paramount to improving quality of life
and maintaining independence.
Current rehabilitation strategies to improve gait and
balance in pwMS predominantly involve exercise partici-
pation to address deficient motor function, with some
consideration given to sensory training [9–13]. These
multimodal approaches have been shown to significantly
improve several clinical and functional measures in
pwMS, including dynamic balance, rate of falls, physical
activity levels, perceived balance confidence, walking
ability and quality of life [9–13]. However, there is an ur-
gent need to develop additional methods to complement
exercise and which target MS sensory impairments [14–
19] to a greater extent, in particular tactile sensation and
proprioception, in order to preserve and enhance mobil-
ity for as long as possible. Previous evidence has shown
that a strong relationship exists between foot sensation
and standing balance performance in pwMS [15]. Simi-
larly, a loss of lower limb proprioception, including joint
position sense at the ankles and feet, in pwMS can detri-
mentally affect gait and standing balance, leading to
greater dependence on compensatory motor mecha-
nisms in order to remain upright [17, 19]. An increasing
body of literature suggests footwear interventions may
be another treatment option to help improve gait per-
formance in pwMS [20–22].
Textured shoe insoles, designed to enhance plantar
sensory information, have been shown to consistently
alter gait patterns in the short-term, potentially improv-
ing walking stability in a range of clinical populations,
including older fallers [23], adults with Parkinson’s dis-
ease [24] and pwMS [20, 21]. To date, exploratory stud-
ies indicate that textured insoles can lead to beneficial
alterations in spatiotemporal gait parameters such as a
reduced ML base of support [20], improved gait kinetics
and kinematics [21] in pwMS. Significant increases in
lower limb muscle activity during both stance and swing
phases of gait, changes in knee and hip excursion and
ground reaction forces, have been found immediately
after pwMS wore textured insoles, with these changes
attributed to enhanced stimulation of plantar mechano-
receptors [21]. Furthermore, after wearing textured in-
soles for 2 weeks, significant increases have also been
observed in stride and step length, and significant de-
creases in the size of the ML base of support during
level-ground walking – interpreted to represent a more
confident gait pattern. These changes were observed in-
dependent of wearing the textured insoles, again sup-
porting the theory that a sensory training effect may
have occurred during the intervention period [20]. How-
ever, recent evidence reports no significant changes ei-
ther in spatiotemporal gait measures during treadmill
walking or plantar sensitivity after wearing textured in-
soles over a longer, 4-week intervention period in pwMS
[25]. It is possible that any effects of textured insoles on
gait may only be identified when walking in conditions
that emulate everyday life [25]. Further, whilst no
changes were observed in plantar sensitivity, alterations
may have occurred in other measures of sensory func-
tion such as foot proprioception [25]. As such, the
short-term effects of textured insoles on mobility, and
their proposed underlying mechanisms in pwMS, remain
unclear. It is possible that the benefits of textured insoles
in pwMS may accrue, and that additional benefits may
be observed, with prolonged wear over 4-weeks, but this
has not yet been explored. Previous work has shown
limited effects of textured insoles on gait and balance
measures in pwMS immediately after wearing the insoles
for the first time, with subsequent improvements ob-
served following 2-weeks of wear [20].
This randomised controlled trial will determine
whether wearing textured shoe insoles for 12-weeks can
improve gait when walking over even and uneven sur-
faces in pwMS. The primary aim of this study is to ex-
plore whether prolonged wear of textured insoles alters
ML base of support (as a measure of walking stability)
from baseline assessment 2 to the post-intervention
assessment. Secondary aims are to explore whether
prolonged wear of textured insoles alters other spatio-
temporal gait parameters including stride length, stride
time variability, double-limb support time and gait vel-
ocity, gait kinematics (specifically lower limb joint and
trunk movement), and changes in the perception of foot
sensation or proprioception, as underlying mechanisms




A prospective, parallel group, single blinded, randomised
controlled trial with 176 pwMS living in the community
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will be conducted, conforming to the Consolidated Stan-
dards of Reporting Trials guidelines [26] (Fig. 1).
Sample size
Sample size has been calculated for the primary outcome
measure, ML base of support during even surface walk-
ing, based on our pilot data [20]. Our preliminary study
reported mean (SD) readings at baseline for base of
support of 13.78 (5.11) cm and a significant mean
change of –1.66 cm (P = 0.02) at 2-weeks post interven-
tion. With a power of 80 %, and alpha level of 0.05, a
calculation for two related groups indicated that 76 par-
ticipants were required in each group. In our pilot study,
we recruited 46 pwMS, with no loss to follow-up across
two visits (although completion of all test procedures
was limited by fatigue in some participants). As this
Fig. 1 Trial design
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randomised controlled trial involves a longer interven-
tion period, we will allow for a 15 % attrition rate. An
85 % retention rate over a 16-week period (baseline as-
sessments at week 0 and week 4, intervention 12-weeks,
post-intervention assessment at week 16) is appropriate
based on previous MS intervention studies. Three ran-
domised controlled trials with 12-week intervention pe-
riods conducted in pwMS, report retention rates of
82 % [27], 88 % [11], and 90 % [28]. Therefore, 88 par-
ticipants per group will be recruited, giving a total of
176 participants.
Location and setting
All assessments will be conducted in the Gait Labora-
tory within the Institute of Health and Biomedical
Innovation at Queensland University of Technology,
Brisbane, Australia.
Participants
Men and women with a diagnosis of MS will be identi-
fied through a pool of sampling frames including MS
Queensland, local MS health care providers and commu-
nity organisations across the Brisbane, Gold Coast and
Logan regions, Australia. Participants will be recruited
through mainstream media advertisements and written
materials distributed to individuals listed on the MS
Queensland database and those attending local MS
clinics. Recruitment procedures will be centrally coordi-
nated by clinical staff working within each organisation
to maintain patient confidentiality. Participants will be
invited to voluntarily contact the Principal Investigator
for further information.
Participants will be eligible to take part if they meet
the following criteria: aged over 18 years; clinical diagno-
sis of MS; ambulant over 100 metres with or without the
use of an assistive device; and Disease Step rating of 1–4
[29]. Participants rated as Disease Step 1 (mild disability:
mild symptoms and/or signs) to 4 (late cane: unable to
walk 25 feet without a cane/unilateral support) will be
eligible to take part in this study, assuming they have
sufficient ambulatory capacity to complete the gait trials.
Exclusion criteria are neurological conditions other
than MS; peripheral neuropathy; currently being pre-
scribed over-the-counter or custom-made foot orthoses;
cardiovascular or orthopaedic conditions including re-
cent injury to the back or legs limiting ambulation; un-
stable psychiatric condition or cognitive impairment
(Short Form Mini-Mental State Examination score <24)
[30]. Furthermore, enrolled participants who report an
exacerbation of MS symptoms persisting >24 h, 4 weeks
prior to, or at any time during, the intervention period
will also be excluded from the study. All participants will
initially be screened via telephone interview and invited
to attend a clinical examination to confirm eligibility.
Written informed consent will be obtained from all par-
ticipants. This study was approved by the Medical
Research Ethics Committee at The University of
Queensland (#2014000781) and University Human Re-
search Ethics Committee at Queensland University of
Technology (#1500000615).
Randomisation and blinding
The concealed randomisation schedule will be estab-
lished using a computer-generated random number se-
quence, and maintained by an offsite investigator who is
neither involved with the enrolment nor with assessment
of participants. Consecutively numbered, randomly or-
dered, opaque envelopes containing group allocation (in
a 1:1 ratio), will be opened consecutively after baseline
assessment 2, by a second research assistant who is only
responsible for administering the insoles. All investiga-
tors and the first research assistant, who are involved in
the enrolment or assessment of participants over the
duration of the trial, will remain blinded to group alloca-
tion. Following baseline assessment 2, the Principal In-
vestigator and first research assistant will leave the gait
laboratory to ensure blinding to the insole condition.
The second research assistant will then fit the partici-
pant with their allocated insole, and provide advice re-
garding the frequency of wear, completion of insole wear
diaries, and emergency contact details for local podiatry
care. Participants will be instructed not to divulge their
group allocation. As it is not possible for participants to
be blinded to their allocated group (those in the inter-
vention group will be able to perceive the textured ma-
terial against the sole of their foot), the full aims of the
study will be concealed. Participants will not be told that
the intervention is designed to provide enhanced plantar
sensory information which could potentially lead to
changes in gait. Such knowledge could influence how
participants walk and they could purposefully alter their
walking patterns between conditions; debriefing will
occur upon completion of the study. Furthermore, cod-
ing of participants will not refer to group.
Intervention
In this randomised controlled trial we will investigate
two different shoe insoles: textured insoles and smooth
(control) insoles. Both insoles have been implemented in
previous research strategies in pwMS [20], older fallers
[23] and middle-aged adults [31]. The textured insole
(Evalite Pyramid ethyl vinyl acetate (EVA), 3 mm thick-
ness, shore value A50, black, OG1549; Algeos PTY Ltd.,
Liverpool, UK) was selected from a range of EVA soling
materials, and has small, pyramidal peaks with centre-
to-centre distances of approximately 2.5 mm. The
smooth control insole (Medium Density EVA, 3 mm
thickness, shore value A50, black, OG1304; Algeos PTY
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Ltd., Liverpool, UK) was chosen from a range of plain
EVA materials and has a flat surface with no indenta-
tions. Insoles will be tailored to each participant’s shoe
size. An experienced podiatrist will oversee and advise
on the delivery of insoles, and any podiatry-related issues
including insole fit, durability and dermatological or per-
ipheral changes at the foot during the intervention
period. Participants will be instructed to wear their allo-
cated insoles, in their own shoes, as much as possible.
All assessments of balance and gait will be conducted
with the participants wearing standardised footwear (Do-
nated by Pacific Brands Australia Pty Ltd), comprising a
basic construct rubber-soled shankless shoe with a soft
canvas upper [32], into which the insoles will be
inserted. This standardisation will control for any pos-
sible insole/shoe interactions across participants, which
could impact the findings. To allow for familiarisation to
the footwear, participants will be instructed to walk for
5 minutes in the standardised shoes prior to testing.
Primary outcome measures
Spatiotemporal gait variables
The primary gait measure will be ML base of support
when walking over an even and uneven surface. Our
pilot study demonstrated that after 2-weeks wear of the
textured insoles, the significant mean reduction in base
of support was 1.7 cm (P = 0.02) compared to baseline
measures [20]. The magnitude of this effect is highly
clinically relevant as previous research indicates a mean
difference of ~2 cm in base of support exists between
pwMS and healthy controls [6, 7]. This suggests that the
textured effect is clinically significant, and may be of suf-
ficient magnitude to reduce base of support to a level
similar to healthy adults.
Secondary outcome measures
Spatiotemporal gait variables
Additional measures of walking stability will include
stride length, stride time variability, double-limb support
time, and gait velocity, when walking over an even and
uneven surface. Our pilot study reported that wearing
textured insoles for 2-weeks led to significant increases
in mean stride length (right leg: 5.8 cm (P < 0.01); left
leg: 4.4 cm (P < 0.01)), compared to baseline assessment
[20]. Details of specific methods underpinning all mea-
sures are provided in the assessment section below.
Gait kinematics
During both even and uneven surface walking trials,
lower limb gait kinematics will be collected using a 3D
motion capture system and will include hip, knee and
ankle joint angles (and their inter-relationships) and
foot-to-floor angle to determine maximum toe clearance.
Segmental measures of trunk inclination, as well as arm
swing, mediolateral pelvis and head displacement will
also be collected. Specific details are presented below.
Sensory measures
Light touch-pressure sensation will be determined by re-
cording the smallest monofilament that the participant
can perceive at five locations on the foot as detailed
below [15]. Vibration sense will be measured using a
digital stop watch, started when the tuning fork touches
the participant’s skin at two sites on the feet, then
stopped when the participant indicates the vibration can
no longer be felt. The average of three trials will be re-
corded for both feet (seconds) [15]. For two-point dis-
crimination, when the participant perceives two stimuli
as one, the distance will be recorded in millimetres
[15]. Ankle joint position sense will be determined by
the participant performing the ankle joint position
sense test [33].
Insole wear and falls
Participants will be followed for 12-weeks with insole
wear self-reported diaries and falls calendars to deter-
mine (1) the number of hours insoles are worn and (2)
the frequency, time, and location of any falls and injur-
ies. In this study, a fall will be defined as an unexpected
event in which the participant comes to rest on the
ground, floor or lower level [34].
Clinical screening examination
Prior to enrolment, all individuals will undergo a clinical
screening examination, conducted by a Specialist Neuro-
logical Physiotherapist (KW), which will include the as-
sessment of disease stage and symptoms including
spasticity and ataxia. Stage of disease will be determined
using Disease Steps [29]. This tool is an assessment of
disability in patients with MS, which has low inter-rater
variability, correlates strongly to the Expanded Disability
Severity Scale at initial assessment (EDSS), and can be
used to monitor disease progression [35]. Spasticity will
be assessed using the Tardieu Scale [36], and ataxia
scored using the Brief Ataxia Rating Scale [37].
Baseline assessments
Demographics, including sex, age, height, and body
mass, will be collected. To characterise the study sample,
participants will be asked to complete questionnaires
that address relevant medical history and medications,
length of time since diagnosis of MS, current MS symp-
toms using the MS Impact Scale (MSIS-29) [38], and
perceived walking ability using the MS Walking Scale
(MSWS-12) [39]. Quality of life, the impact of fatigue
and pain, and perceived disability will be assessed using
four self-report questionnaires: MS Quality of Life In-
strument (MS QoL-54) [40]; Modified Fatigue Impact
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Scale (a questionnaire which measures how MS-related
fatigue affects everyday life including physical, cognitive
and psychosocial functioning [41]); Medical Outcomes
Study (MOS) Pain Effects Scale (a MS-specific question-
naire which assesses how pain and disturbing sensations,
such as burning or tingling, affect everyday life [42]);
and the Perceived Deficits Questionnaire (a MS-specific
questionnaire which assesses several domains of cogni-
tive function that are commonly affected by MS, namely
attention, retrospective memory, prospective memory,
planning and organisation [43]). Number of self-reported
falls experienced in the previous 12 months will be re-
corded, and current fear of falling assessed using the Falls
Efficacy Scale-International [44].
Following the clinical screening examination, all par-
ticipants will complete initial assessments of gait, foot
sensation and proprioception (baseline assessment 1).
Standing balance and activity levels will also be mea-
sured at baseline assessment 1 only. Each participant will
receive a wireless activity monitor (activPAL, Glasgow,
Scotland), to be worn every day for seven consecutive
days, allowing us to characterise the activity of the study
group, monitor habitual weekly activity levels and estab-
lish any relationships with gait performance at baseline.
The increasing use of accelerometry in pwMS [45, 46] is
accredited to its ability to allow monitoring of changes
in walking impairments with disease progression (e.g.
worsening of MS) or disease activity (e.g. acute relapse),
over long periods of time [47]. Four weeks after base-
line assessment 1, a second baseline assessment (base-
line assessment 2) will be conducted. The purpose of
this 4-week waiting period is to establish each partici-
pant’s natural rate of MS disease progression, specific-
ally the magnitude of change in the primary and
secondary outcome measures of gait, foot sensation and
proprioception, prior to delivery of the intervention.
Gait
Gait performance will be evaluated by completing a
12 m walk over an even surface and an uneven surface.
The even surface will consist of a level, vinyl material:
the top cover of an instrumented walkway (GAITRite®,
CIR Systems, Inc., Havertown, PA 19083, USA). The
GAITRite® system is an electronic walkway, approxi-
mately 8.2 m long (the active area being 0.61 m wide
and 7.32 m long), which has been shown to have high
reliability [48, 49]. The uneven surface (placed directly
on the laboratory floor, adjacent to the GAITRite® walk-
way) will consist of two layers of thick soft foam, over
which small blocks of wood of uneven shapes and sizes
will be spread in a random manner, with a top layer of
artificial grass covering the walkway, using previously
described methods [50]. Maintenance of stability when
walking requires individuals to control their centre of
mass within a constantly changing base of support; this
becomes even more challenging when the surface is un-
even, increasing the risk of loss of balance, resulting in a
fall. Deficits in balance control during walking or, con-
versely, the therapeutic benefit of interventions (such as
shoe insoles) on walking performance may only become
apparent when the balance challenge is sufficiently de-
manding. The uneven walking surface will emulate a
situation encountered in daily life. A start and finish line
will be marked on the floor 2 m in front and 2 m behind
both the even and uneven surface walkways, allowing
participants to accelerate and decelerate outside the
walkways [48]. Participants will be positioned at the start
line and instructed to walk at their comfortable, self-
selected walking pace. Five walking trials will be com-
pleted on the even surface and five trials on the uneven
surface, each whilst barefoot, wearing standardised foot-
wear only, and wearing two different shoe insoles (tex-
tured and smooth) within standardised footwear. The
test sequence (footwear condition, surface) will be ran-
domised. Spatiotemporal gait variables will be measured
using the GAITRite® system (sampling rate 80 Hz) when
walking over the even surface, and using an 11-camera
Vicon® motion capture system (Vicon, 6 ×MX13 and
5 × T40 cameras, giganet control box, with a MX Net
and Mx Link), sampled at 200 Hz, when walking over
the uneven surface. Participants will have multiple re-
flective markers attached to their body, following the
Vicon PlugIn Gait full body model. The Vicon system
records the position of reflective markers placed at stan-
dardised anatomical sites on the upper and lower body
and will be used to measure spatiotemporal gait vari-
ables and gait kinematics.
Balance
Standing balance will be assessed to provide a measure
of basic, unperturbed postural stability. Participants will
stand on an AMTI force platform (sampling rate
1000 Hz), using a standardised foot position (heels
placed 1/10th participants height apart and angled to 14°
[51]), and arms hanging by their sides, for 30 seconds
[52]. Double-limb standing tests will be performed on a
firm and foam surface, with their eyes open and eyes
closed. To prevent vestibular disruption when standing
with eyes open, participants will be instructed to look
straight ahead and focus on the middle of a black circu-
lar visual target (10 cm diameter), mounted onto a board
positioned 3 m from the centre of the force platform,
and adjusted to the eye level of each participant. Stand-
ing balance will be assessed whilst barefoot, wearing
standardised footwear only, and when wearing two differ-
ent shoe insoles (textured and smooth) within standar-
dised footwear. The test sequence (footwear condition,
surface, vision) will be randomly presented. Measures of
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baseline standing balance will include centre of pressure
path velocity, range and standard deviation of centre of
pressure movement in the anterior-posterior and ML
directions.
Foot sensation and proprioception
Somatosensory function, including light touch-pressure
sensation, vibration sense, and two-point discrimination,
will be assessed. Semmes-Weinstein monofilaments
(smallest (1.65) to largest (6.65)) will be used to deter-
mine light touch-pressure sensation at five locations on
the foot, namely the plantar surface of the great toe, first
metatarsal head, fifth metatarsal head, heel, and dorsum
of the foot between the first and second toes [53]. The
monofilaments will be applied perpendicular to the skin
for 1.5 seconds, and the participant will be required to
indicate whether the fibre can be felt. The smallest
monofilaments (1.65–4.08) will be applied three times
consecutively, whilst larger ones (4.17–6.65) will be ap-
plied only once [15]. Duration of vibration sense will be
measured using a 128-Hz frequency tuning fork at the
first metatarsal head and medial malleoli of both feet
[15]. The ability to distinguish between two light-touch
stimuli (two-point discrimination) will be measured
using an aesthesiometer applied to the skin at three foot
regions: tip of the great toe, first to second metatarsal
interspace, and fifth metatarsal head. Each region will be
touched with either one or two points simultaneously in
a random order, with approximately 2 seconds between
each application of the stimuli. Assessment will begin
with the two stimuli at the maximum distance apart,
and decrease until the participant can no longer differ-
entiate the two points [15]. Foot position awareness will
be assessed bilaterally using the ankle joint angle
reproduction test [33]. The investigator will passively set
the participant’s ankle joint to three pre-determined an-
gles in plantarflexion and dorsiflexion directions, relative
to a neutral foot position. A variable time and trajectory
will be used when positioning the foot in order to elim-
inate extraneous cues and psychophysical processes. The
participant will be asked to reposition the ankle joint at
the target angle by moving only the foot segment. Ac-
curacy in joint positioning will be determined by meas-
uring the difference between the target and actual
angles using an internet-based goniometer [54]. This
application has been shown to be a valid method for
measuring joint angles and has a high level of inter-
rater (ICC2,1 = 0.96 to > 0.99) and intra-rater (ICC =
all > 0.99) reliability [54].
Post-intervention assessment
Gait, foot sensation and proprioception will be assessed
within 2 weeks of the end of the 12-week intervention
period, using the same procedures employed at baseline.
A 12-week intervention period will provide maximal
time to allow for the accrual of any sensory training ef-
fects and accumulation of meaningful changes in out-
come measures, in particular for participants with MS
who show minimal gait disturbance at baseline and cur-
rently engage in an active lifestyle. This intervention
period is consistent with previous randomised controlled
trial intervention studies conducted in pwMS [11, 27,
28], and footwear intervention trials [55, 56]. This final
point of assessment will (1) quantify whether any imme-
diate changes in gait, observed at baseline, have accrued
over time, or if additional effects can be seen and (2) de-
termine whether there are any alterations in the percep-
tion of foot sensation or proprioception, which may
suggest the insoles have a sensory training effect. Partici-
pants will be asked to return their insole wear diaries and
falls calendars at this time. Participants will also be asked
to rate the level of comfort experienced when wearing the
insoles by way of a series of 100 mm visual analogue scales
used in previously published research [57].
Data analysis
All analyses will be conducted in a blinded manner, on
an intention-to-treat basis, with the alpha set to 0.05.
We will explore frequency distributions, percentages and
calculate means and standard deviations for the outcome
measures. Differences between intervention and control
groups in spatiotemporal gait variables, gait kinematics,
foot sensation or proprioception, over the intervention
period, will be explored using General Linear Models
(repeated measures analysis of variance, ANCOVA), in a
two group (smooth control insole; textured insole) by
three phase (baseline assessment 1, baseline assessment
2, post-intervention) model. We will adjust for potential
confounding variables (e.g. age, sex, disease duration) by
using these as covariates. Non-parametric tests will be
used where data is not normally distributed or violates
the assumption of sphericity. Multiple regression model-
ling will be used to determine any relationships between
foot sensation, proprioception and measures of gait per-
formance. Data will be analysed using SPSS version 22
(SPSS Inc., Chicago, IL 60606, USA).
Discussion
Gait impairment is one of the most disabling and debili-
tating complaints reported by pwMS [5]. Deteriorating
mobility observed in the early stages of disease [6–8] not
only increases the risk of falling [1, 2], but frequently
culminates in a complete loss of walking ability in the
advanced stages [58]. The associated personal and soci-
etal burdens can have devastating implications for the
individual, their families and national health services.
Physical rehabilitation strategies reported to improve
gait in pwMS commonly involve short-term multi-
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component exercise programs [9–13]. Maintenance of
walking stability is attributed to optimal sensorimotor
function; however, therapeutic management of gait im-
pairments in pwMS largely focuses on addressing motor
problems and poor aerobic capacity, and to a lesser ex-
tent sensory training, which is commonly addressed
purely by way of balance tasks under a variety of sensory
conditions. Interventions targeting sensory impairments
at a more local level, including foot sensation and lower
limb proprioception, are not frequently incorporated.
This is a crucial area to address, as loss of foot sensation
and impaired lower limb proprioception are strongly as-
sociated with standing balance and gait performance in
pwMS [15, 19]. Therefore, the effectiveness of current
strategies for managing mobility in pwMS could be fur-
ther enhanced by using a wider range of treatment
techniques.
Providing enhanced sensory input to the plantar sur-
face of the feet has recently been considered a potential
mechanism through which footwear interventions may
improve gait [21, 22, 24, 59–63] by way of altering sen-
sorimotor function. Underlying physiological mecha-
nisms by which a textured insole may initiate changes in
gait are suggested to include the provision of sufficient
tactile stimulation to alter the rate of discharge from
mechanoreceptors or firing patterns of populations of
sensory afferents located in the feet. Textured shoe insoles
appear to have the capacity to alter gait patterns, poten-
tially improving gait stability in ageing, neurodegenerative
and neuromuscular disease groups with known balance
impairments. To date, exploratory studies report that
wearing shoe insoles deigned to enhance plantar sensation
can significantly increase single-limb support time [24],
increase stride length and reduce double-limb support
time [32] during walking in people with Parkinson’s dis-
ease. Similar conclusions are emerging for pwMS, with
exploratory work observing beneficial alterations in
spatiotemporal gait parameters [20], gait kinetics and
kinematics [21].
This randomised controlled trial will use fundamental
knowledge of sensory and motor function in MS to de-
velop novel ways to improve gait by way of enhancing
sensory information at the soles of the feet. Preliminary
work in this clinical population [20] provides strong evi-
dence of improvements in gait patterns when textured
insoles were worn (as a single intervention) for 2 weeks.
It is possible that the benefits of wearing textured insoles
may accrue, and that additional benefits may be ob-
served, over a longer period of time. Findings from this
trial could have implications on the management of gait
impairment in pwMS. The benefit for pwMS (and their
families) is that this study may lead to the development
of a new, evidence-based footwear intervention which is
inexpensive, non-invasive, promotes self-management by
the user, and has the capacity to enhance mobility and
independent living. Furthermore, addressing problems
with mobility, and subsequently quality of life, could
have a major economic impact through improvements
in productivity or reducing working days lost. The bene-
fit for healthcare professionals is that this study may
generate vital evidence to inform the development of
more effective, multi-faceted and multi-disciplinary re-
habilitation programmes, which are tailored to address a
greater range of MS-specific impairments that contrib-
ute to deteriorating gait. This could have major implica-
tions on current clinical guidelines and policy relating to




EVA: Ethyl vinyl acetate; ML: Mediolateral; MS: Multiple sclerosis; pwMS: People
with multiple sclerosis.
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